We've received your inquiry. A specialist will reach out within 1 business day.
Start over
This article could contain syndicated content. We have not reviewed, approved, or endorsed the content and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here
Announced the publication of its Phase II MAvERIC study results in the Journal of the American Heart Association. The publication comes as the pivotal Phase III MAVERIC trial nears full patient enrollment. Cardiol Therapeutics Inc. shares T.CRDL are trading unchanged at $1.50.
| Symbol | Last | Chg | %Chg |
|---|---|---|---|
| CRDL.TO | 1.67 | -0.07 | -4.02% |
| Cardiol Therapeutics Inc | |||
/Microsoft%20headquarters%20By%20Peter.jpeg)
/Micron%20Technology%20Inc_%20logo%20on%20building-by%20vzphotos%20vis%20iStock.jpg)
/NVIDIA%20Corp%20logo%20outside%20building-by%20BING-JHEN_HONG%20via%20iStock.jpg)
/Amazon%20-%20Image%20by%20bluestork%20via%20Shutterstock.jpg)